New drug duo aims to outsmart resistant lung cancer
NCT ID NCT07322783
Summary
This study is testing whether adding a drug called savolitinib to a standard drug (osimertinib) can help control advanced lung cancer that has developed resistance to treatment. It is for adults whose cancer has specific genetic changes (EGFR mutation and low-level MET amplification) and has progressed after prior therapies. The goal is to see if this combination can shrink tumors and delay cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qingdao Central Hospital
RECRUITINGQingdao, 266042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.